1 Schering-Plough Research Institute, 2015 Galloping Hill Road, 4700 Kenilworth, NJ 07033; 2 Department of Medicine and Division of Infectious Diseases, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA; 3 Departamento de Immunologia, Microbiologia y Parasitologia, Facultad de Medicina y Odontologia, Universidad del Pais Vasco, Bilbao, Vizcaya, Spain
Received 24 July 2003; returned 15 September 2003; revised 13 October 2003; accepted 19 October 2003
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Materials and methods: Seven sequential C. albicans isolates were cultured from an AIDS patient treated with posaconazole for refractory oropharyngeal candidiasis. Expression levels of the CDR1, CDR2 and MDR1 genes, encoding efflux pumps previously implicated in azole resistance, and ERG11, encoding the azole target site, were monitored using northern blot and real-time PCR. The ERG11 genes from all seven isolates were sequenced.
Results: The seven closely related isolates exhibited significant decreases in susceptibility to fluconazole (MIC 32 mg/L) and voriconazole (MIC
2 mg/L) and progressive decreases in susceptibility to both posaconazole (isolates 14 MIC 0.25 mg/L, isolates 57 MIC 2 mg/L) and itraconazole (isolates 14 MIC 1 mg/L, isolates 57 MIC > 8 mg/L). None of the isolates exhibited any significant changes in the expression levels of ERG11 or the efflux pump genes. All seven isolates had multiple mutations in ERG11; isolates one through four each had five missense mutations; four of the resultant amino acid changes were previously associated with azole resistance. The fifth isolate had an additional novel mutation in one copy of ERG11, resulting in a Pro-230 to Leu substitution. This mutation was present in both ERG11 genes in the last two isolates. Select ERG11 genes were expressed in Saccharomyces cerevisiae, the ERG11 allele with all six mutations conferred the highest level of posaconazole resistance.
Conclusions: Multiple mutations in ERG11 are required to confer decreased susceptibility to posaconazole.
Keywords: azoles, drug resistance, ERG11, efflux pumps
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Posaconazole (SCH56592) is a potent, novel, broad-spectrum triazole in Phase III trials. Both in vitro and in vivo testing have demonstrated that posaconazole is more effective than fluconazole against Candida spp. and Aspergillus spp.12 In this study we analysed a collection of related C. albicans isolates from a patient undergoing azole therapy, to better understand the molecular basis of resistance to posaconazole. We identified specific amino acid substitutions in Erg11p, including a novel substitution, and correlated changes in susceptibility with the occurrence of specific mutations (part of this work was presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, September 2002).
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Clinical C. albicans isolates were obtained by oral saline rinses. Saccharomyces cerevisiae strain YKKB-13 and plasmid YEp51 were obtained from D. Sanglard, Institut de Microbiologie, Universitaire Vaudois. C. albicans strain C43 is an azole-susceptible clinical isolate from the Schering-Plough Research Institute (SPRI; Kenilworth, NJ, USA) culture collection.
Antifungal agents
Posaconazole was prepared at SPRI as a micronized powder. Fluconazole and the parenteral formulation of voriconazole were obtained from Pfizer Inc. (New York, NY, USA). Itraconazole and amphotericin B powders were obtained from Janssen Pharmaceutica Inc. (Beerse, Belgium) and Sigma Chemical Co. (St Louis, MO, USA), respectively. All drugs, except voriconazole (which was dissolved in water) were dissolved in DMSO, dilutions were made in RPMI 1640 media (BioWhittaker, Walkersville, MD, USA).
Antifungal drug susceptibility testing
The MICs for C. albicans strains were determined according to the procedures of the NCCLS.13
Strain identification
The identity of the clinical isolates was confirmed using the following tests: the Vitek Identification System with the Yeast Biochemical Card (bioMérieux Vitec Inc, Hazelwood, MO, USA), germ tube formation in serum-containing medium and colour of colonies on CHROMagar Candida medium (CHROMagar, Paris, France). Karyotyping, restriction fragment length polymorphism (RFLP) analysis using SfiI, and subsequent probing of SfiI digests by Southern blotting using the Ca3 probe, were all carried out as described previously.6 Repetitive element PCR (Rep-PCR) analysis was carried out using the DiversiLab Candida kit as directed by the manufacturer (Bacterial BarCodes, Houston, TX, USA). The 10 C. albicans isolates used for comparative purposes were randomly chosen from the SPRI culture collection.
Measurement of transcript levels
Strains were propagated in yeast peptone dextrose (YPD, Qbiogene) medium and harvested at mid-logarithmic growth phase. Total RNA was extracted using the RNAeasy mini kit (Qiagen Inc., Valencia, CA, USA). Probe preparation, northern blots and quantification of signals were all carried out as described previously.6 Real-time PCR analysis was carried out as described previously.14 Reactions were run in duplicate and repeated at least once, relative gene expression levels (CT) were calculated using an 18S rRNA internal control.
PCR amplification and sequencing of ERG11
The ERG11 alleles were PCR amplified in overlapping 600 base pair (bp) segments from total genomic DNA. Both strands of the PCR fragments were sequenced directly by MWG-Biotech Inc. (High Point, NC, USA) and the sequences were compared with the published sequence (GenBank accession number X13296).
Cloning of ERG11 alleles
The ERG11 alleles were PCR amplified from chromosomal DNA with the following oligonucleotides to generate fragments with flanking SalI and BamHI restriction sites; 5'-ACGCGTCGACAATATGGCTATTGTTGAAACTGTC-3' and 5'-GCGGATCCTTAAAACATACAAGTTTCTCTTTT-3'. To mutate codon 230, the 5'-region and 3'-regions of ERG11 were separately PCR amplified (oligonucleotides: 5'-region, 5'-TGTAAAACGACGGCCAGTATGATTATTAAACTTCTTTGCGTCCATCCA-3' and 5'-AACAAAATTAATAAGGGTAAAACCTTTATC-3'; 3'-region, 5'-GATAAAGGTTTTACCCTTATTAATTTTGTT-3' and 5'-CAGGAAACAGCTATGACCTCATGGCGACCACACCCGTCCT-3') to introduce the required nucleotide substitution at codon 230. Using fusion PCR, the two halves were fused together using the same oligonucleotides used to clone the full-length genes. In all cases, the PCR products were cloned into the multicopy plasmid YEp51, sequenced to verify amplification, and then used to transform S. cerevisiae strain YKKB-13 to leucine prototrophy. We note that compared to the sequence published in GenBank, the ERG11 genes from the azole-susceptible C. albicans strains C43 encode a E266D substitution.
Spotting tests
S. cerevisiae transformants, expressing various ERG11 alleles, were suspended in YNB broth (Qbiogene, Carlsbad, CA, USA) supplemented with 2% raffinose and 2% galactose to achieve an OD530 of 0.1. Serial 10-fold dilutions of this inoculum were spotted on YNB plates supplemented with 2% raffinose, 2% galactose and azoles at various concentrations. The plates were incubated at 35°C for 72 h.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
An AIDS patient was diagnosed with oropharyngeal candidiasis (OPC) and was treated initially with amphotericin B (Abelcet) for 2 months and then with itraconazole for 5 months. At the end of this time a C. albicans isolate (C369, Table 1) with reduced susceptibility to fluconazole, voriconazole and itraconazole was cultured from the patient. The patient was switched to posaconazole therapy and received 400 mg posaconazole twice a day for approximately 6 months (November 1998 to June 1999). During this time, three C. albicans isolates (C378, C371 and C372) were cultured from the patient. Less than 1 month after discontinuation of posaconazole therapy, the patient experienced a recurrence of OPC and was treated with both low and high doses of voriconazole. There was no clinical improvement and in August 1999, the patient was enrolled in a long-term clinical study and treated with posaconazole as above. The patient again responded positively to drug therapy but after 9 months (May 2000), the patient experienced a relapse, therapy was discontinued and the patient was diagnosed as a treatment failure. Three additional C. albicans isolates (C373, C376 and C375) were obtained during this second course of posaconazole therapy.
|
Isolate C369 was obtained before posaconazole treatment. Five additional isolates were cultured from the patient over the course of the two periods of posaconazole therapy (see above) and a final isolate (C375) was obtained immediately after discontinuation of posaconazole therapy. All seven isolates were identified as C. albicans. Five of the seven isolates were tested using karyotyping and RFLP mapping using SfiI. All five yielded nearly identical banding patterns suggesting that they are closely related (Figure 1a and b). In addition, Rep-PCR analysis of all seven strains yielded nearly identical profiles (Figure 1c). When these profiles were compared with those obtained from 10 randomly chosen C. albicans clinical isolates, the isolates from this study clearly grouped together. Finally, a further indication of relatedness came from the finding that the seven isolates had acquired 12 identical mutations (seven silent and five missense, see below) in the ERG11 genes.
|
All of the isolates were susceptible to amphotericin B (Table 1). However, all seven isolates exhibited marked reductions in susceptibilities to azoles. According to NCCLS guidelines,13 all seven isolates were itraconazole-resistant (MIC 1 mg/L), the middle three isolates were fluconazole-resistant (MIC
64 mg/L) and the remainder were susceptible dose-dependent (SDD, MIC 1632 mg/L). There are no breakpoints established for either voriconazole or posaconazole. However, based on a sample size of 4195 isolates, the MIC at which 90% of clinical C. albicans isolates were inhibited (MIC90) by voriconazole was 0.03 mg/L.15 Compared to this baseline value, the seven isolates exhibited on average a >100-fold decrease in susceptibility to voriconazole. Based on a sample size of 1900 strains, the MIC90 for posaconazole was 0.06 mg/L.16 Compared to this baseline value, the first four and the last three isolates exhibited four-fold and 30-fold decreases in posaconazole susceptibility, respectively.
Expression levels of efflux pump and ERG11 genes
Azole resistance has been associated with up-regulation of genes encoding efflux pumps and/or ERG11. We therefore quantified transcript levels of CDR1, CDR2, MDR1 and ERG11 in exponentially growing cultures using both northern blot analysis and real-time PCR. Northern blot analysis of five of the isolates revealed no significant changes in ERG11, MDR1 and CDR1 transcript levels (Figure 2a). However, the last two strains in the series, C376 and C375, exhibited minor (approximately three-fold) increases in CDR2 transcript levels. Real-time PCR was used to compare expression levels in the baseline strain, C369, with those in strains C373 and C375. Consistent with the northern blot analysis, the only changes in expression were minor (two- to three-fold) increases in expression of CDR2 in C373 and C375 (Figure 2b).
|
The ERG11 genes from the seven isolates were sequenced. Compared to the published sequence from an azole-susceptible strain, the seven isolates all had the same seven silent mutations scattered throughout ERG11 (data not shown). In addition, all seven isolates had the same five missense mutations; the resultant amino acid substitutions are shown in Table 2. The fifth isolate in the series, C373, had acquired an additional mutation in one copy of the ERG11 gene resulting in a proline to leucine substitution at residue 230 (P230L). The last two isolates, C376 and C375, were homozygous for this mutation.
|
To verify that the amino acid substitutions in Erg11p were responsible for changes in azole susceptibility, the ERG11 alleles from an azole-susceptible strain, C43, along with those from isolates C369 and C375, were expressed in S. cerevisiae. The pattern of azole resistance in S. cerevisiae mirrored that seen in the original C. albicans isolates: the ERG11 alleles from isolates C369 and C375 conferred reduced susceptibility to posaconazole (Figure 3), itraconazole, fluconazole and voriconazole (data not shown). The ERG11 allele from isolate C375, which encodes the P230L substitution, conferred the highest levels of posaconazole (Figure 3) and itraconazole resistance (data not shown). However, the P230L substitution did not appear to impact resistance to voriconazole as the ERG11 alleles from C369 and C375 conferred the same levels of resistance to voriconazole (data not shown). The P230L substitution was introduced into an otherwise wild-type ERG11 gene and expressed in S. cerevisiae as above; by itself, the P230L substitution did not cause any change in the strains susceptibility to any of the azoles tested above (data not shown).
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Three additional isolates were cultured from the patient after resumption of posaconazole therapy to treat a recurrence of refractory OPC. The first isolate was obtained after 5 months of therapy, a second isolate was obtained 3 months later and the final isolate was collected a month later, immediately after the termination of posaconazole therapy. All three isolates exhibited additional reductions in susceptibility to posaconazole and itraconazole, but no further changes in susceptibility to voriconazole or fluconazole. Molecular typing techniques (and the sequence of the ERG11 gene) confirmed that the three isolates were closely related to the prior isolates suggesting this was a breakthrough infection, rather than a new one. Compared to the baseline isolate, there were no large increases in either pump or ERG11 gene expression. Sequence analysis of ERG11 identified a sixth mutation in one copy of ERG11 in the first of these additional isolates, the next two isolates were homozygous for this mutation. The resulting substitution, P230L, appears to be novel. We confirmed that the P230L substitution was responsible for the additional decrease in posaconazole susceptibility by demonstrating that expression of this allele in S. cerevisiae conferred an elevated level of posaconazole resistance.
The first four isolates of the series had mutations in the C. albicans ERG11 gene that caused dramatic changes in their susceptibility to fluconazole and voriconazole, without significantly affecting posaconazole susceptibility. This is consistent with previous studies looking at azole resistance in both C. albicans21 and in Aspergillus fumigatus.22 These effects presumably result from differences in the way the azoles interact with Erg11p. All azoles interact with the haem cofactor of Erg11p via coordination between the free nitrogen on the triazole ring and the haem iron in the active site cavity of the enzyme. The Erg11p substitutions that specifically reduced binding of fluconazole and voriconazole are proposed to interfere with either the entry into and/or binding to the active site (K128T and Y132H), or are located close to the key cysteine residue involved in haem coordination (G464S).23 The fact that these mutations have relatively minor effects on posaconazole and itraconazole binding suggests that these azoles make additional contacts elsewhere in Erg11p. In a three-dimensional model of Erg11p constructed in-house,24 the long side chains of posaconazole and itraconazole (Figure 4) are enclosed within a channel and are predicted to make extensive hydrophobic contacts along their entire lengths. In the same model, Pro-230 is in close contact with the distal end of the posaconazole/itraconazole side chains and presumably the P230L substitution acts by disrupting binding of this segment of the drugs. However, it is important to note that the P230L substitution alone is not sufficient to disrupt binding of posaconazole and itraconazole; the presence of some, or all, of the additional substitutions is required to cause a shift in the posaconazole MIC.
|
![]() |
Acknowledgements |
---|
![]() |
Footnotes |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
2 . Vanden Bossche, H., Dromer, F., Improvisi, I. et al. (1998). Antifungal drug resistance in pathogenic fungi. Medical Mycology 36, 11928.[CrossRef]
3
.
Latgé, J.-P. (1999). Aspergillus fumigatus and aspergillosis. Clinical Microbiology Reviews 12, 31050.
4
.
Ghannoum, M. A. & Rice, L. B. (1999). Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clinical Microbiology Reviews 12, 50117.
5 . Sanglard, D. & Odds, F. C. (2001). Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infectious Diseases 2, 7385.[ISI]
6
.
Perea, S., Lopez-Ribot, J. L., Kirkpatrick, W. R. et al. (2001). Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy 45, 267684.
7
.
Kelly, S. L., Lamb, D. C. & Kelly, D. E. (1999). Y132H substitution in Candida albicans sterol 14-demethylase confers fluconazole resistance by preventing binding to haem. FEMS Microbiology Letters 180, 1715.[CrossRef][ISI][Medline]
8
.
Lamb, D. C., Kelly, D. E., White, T. C. et al. (2000). The R467K amino acid substitution in Candida albicans sterol 14-demethylase causes drug resistance through reduced affinity. Antimicrobial Agents and Chemotherapy 44, 637.
9 . White, T. C. (1997). Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrobial Agents and Chemotherapy 41, 14827.[Abstract]
10 . Kelly, S. L., Lamb, D. C., Kelly, D. E. et al. (1997). Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Letters 400, 802.[CrossRef][ISI][Medline]
11 . Geber, A., Hitchcock, C. A., Swartz, J. E. et al. (1995). Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrobial Agents and Chemotherapy 39, 270817.[Abstract]
12
.
Cacciapuoti, A., Loebenberg, D., Corcoran, E. et al. (2000). In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrobial Agents and Chemotherapy 44, 201722.
13 . National Committee for Clinical Laboratory Standards. (1997). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A. NCCLS, Wayne, PA, USA.
14
.
Brieland, J., Essig, D., Jackson, C. et al. (2001). Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice. Infection and Immunity 69, 504655.
15
.
Pfaller, M. A., Messer, S. A., Hollis, R. J. et al. (2002). In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrobial Agents and Chemotherapy 46, 17237.
16
.
Pfaller, M. A., Messer, S. A., Hollis, R. J. et al. (2001). In vitro activities of posaconazole (SCH56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy 45, 28624.
17
.
Favre, B., Didmon, M. & Ryder, N. S. (1999). Multiple amino acid substitutions in lanosterol 14-demethylase contribute to azole resistance in Candida albicans. Microbiology 145, 271525.
18
.
Marichal, P., Koymans, L., Willemsens, S. et al. (1999). Contribution of mutations in the cytochrome P450 14-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 145, 270113.
19
.
Sanglard, D., Ischer, F., Koymans, L. et al. (1998). Amino acid substitutions in the cytochrome P-450 lanosterol 14-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrobial Agents and Chemotherapy 42, 24153.
20
.
White, T. C. Holleman, S., Dy, F. et al. (2002). Resistance mechanisms in clinical isolates of Candida albicans. Antimicrobial Agents and Chemotherapy 46, 170413.
21 . Sanglard, D., Ischer, F. & Bille, J. (2002). Interactions of ravuconazole (RVZ) with yeast multidrug efflux transporters and different cytochrome P450 mutant forms. In 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract M-221, p. 379. American Society for Microbiology, Washington, DC, USA.
22
.
Manavathu, E. K., Cutright, J. L., Loebenberg, D. et al. (2000). A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). Journal of Antimicrobial Chemotherapy 46, 22934.
23
.
Podust, L. M., Poulos, T. L. & Waterman, M. R. (2001). Crystal structure of cytochrome P450 14-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proceedings of the National Academy of Sciences, USA 98, 306873.
24
.
Xiao, L., Madison, V., Chau, A. S. et al. (2004). Three-dimensional models of the wild-type and mutated forms of the cytochrome P450 14-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into the binding of posaconazole. Antimicrobial Agents and Chemotherapy 48, in press.